Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 5
2003 6
2004 9
2005 21
2006 22
2007 29
2008 20
2009 21
2010 21
2011 18
2012 6
2013 12
2014 9
2015 6
2016 6
2017 6
2018 10
2019 7
2020 9
2021 6
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

224 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Kahn SE, et al. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. N Engl J Med. 2006. PMID: 17145742 Free article. Clinical Trial.
The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than wa …
The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazon …
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Morley LC, et al. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article. Review.
We assessed statistical heterogeneity using the I(2) statistic and reported quality of the evidence for primary outcomes using GRADE methodology. MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-in …
We assessed statistical heterogeneity using the I(2) statistic and reported quality of the evidence for primary outcomes using GRADE methodo …
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Liao L, Tian YJ, Zhao JJ, Xin Y, Xing HY, Dong JJ. Liao L, et al. Chin Med J (Engl). 2011 Mar;124(5):714-8. Chin Med J (Engl). 2011. PMID: 21518564 Clinical Trial.
METHODS: Fifty-eight women with PCOS were randomly assigned to two groups. Metformin group (29) was treated with metformin mono-therapy and metformin plus rosiglitazone group (29) was treated with metformin plus rosiglitazone for 6 months …
METHODS: Fifty-eight women with PCOS were randomly assigned to two groups. Metformin group (29) was treated with metformin mon …
Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes.
Stage TB, Christensen MH, Jørgensen NR, Beck-Nielsen H, Brøsen K, Gram J, Frost M. Stage TB, et al. Bone. 2018 Jul;112:35-41. doi: 10.1016/j.bone.2018.04.004. Epub 2018 Apr 12. Bone. 2018. PMID: 29654849 Free article. Clinical Trial.
Allocation of insulin regimens was not associated with different levels of BTMs. Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP). Neither metformin nor rosiglitazone pla …
Allocation of insulin regimens was not associated with different levels of BTMs. Metformin and metformin + rosiglitazone …
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Tang T, et al. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003053. doi: 10.1002/14651858.CD003053.pub4. Cochrane Database Syst Rev. 2010. PMID: 20091537 Updated. Review.
However, clinical pregnancy rates are improved for metformin versus placebo (Pooled OR = OR 3.86, 95% C.I. 2.18 to 6.84) and for metformin and clomiphene versus clomiphene alone (Pooled OR =1.48, 95% C.I. 1.12 to 1.95) ). ...Therefore, the use of metformin in …
However, clinical pregnancy rates are improved for metformin versus placebo (Pooled OR = OR 3.86, 95% C.I. 2.18 to 6.84) and for m …
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Tang T, et al. Cochrane Database Syst Rev. 2012 May 16;(5):CD003053. doi: 10.1002/14651858.CD003053.pub5. Cochrane Database Syst Rev. 2012. PMID: 22592687 Updated. Review.
However, clinical pregnancy rates were improved for metformin versus placebo (pooled OR 2.31, 95% CI 1.52 to 3.51, 8 trials, 707 women) and for metformin and clomiphene versus clomiphene alone (pooled OR 1.51, 95% CI 1.17 to 1.96, 11 trials, 1208 women). ...Therefor …
However, clinical pregnancy rates were improved for metformin versus placebo (pooled OR 2.31, 95% CI 1.52 to 3.51, 8 trials, 707 wome …
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Tang T, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003053. doi: 10.1002/14651858.CD003053.pub3. Cochrane Database Syst Rev. 2009. PMID: 19821299 Updated. Review.
However, clinical pregnancy rates are improved for metformin versus placebo (Pooled OR = OR 3.86, 95% C.I. 2.18 to 6.84) and for metformin and clomiphene versus clomiphene alone (Pooled OR =1.48, 95% C.I. 1.12 to 1.95) ). ...Therefore, the use of metformin in …
However, clinical pregnancy rates are improved for metformin versus placebo (Pooled OR = OR 3.86, 95% C.I. 2.18 to 6.84) and for m …
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Lord JM, Flight IH, Norman RJ. Lord JM, et al. Cochrane Database Syst Rev. 2003;(3):CD003053. doi: 10.1002/14651858.CD003053. Cochrane Database Syst Rev. 2003. PMID: 12917943 Updated. Review.
Fifteen trials were included for analysis, 13 of them using metformin and involving 543 participants. MAIN RESULTS: Meta-analysis showed that metformin is effective in achieving ovulation in women with PCOS with odds ratios of 3.88 (CI 2.25 to 6.69) for metformin …
Fifteen trials were included for analysis, 13 of them using metformin and involving 543 participants. MAIN RESULTS: Meta-analysis sho …
Rosiglitazone does not alter the pharmacokinetics of metformin.
Di Cicco RA, Allen A, Carr A, Fowles S, Jorkasky DK, Freed MI. Di Cicco RA, et al. J Clin Pharmacol. 2000 Nov;40(11):1280-5. J Clin Pharmacol. 2000. PMID: 11075314 Clinical Trial.
This study evaluated the effects of the coadministration of these two agents on the pharmacokinetics of both rosiglitazone and metformin. Sixteen male volunteers (22-55 years old) received oral metformin (500 mg every 12 hours), rosiglitazone (2 mg eve …
This study evaluated the effects of the coadministration of these two agents on the pharmacokinetics of both rosiglitazone and met …
[Effect of metformin and rosiglitazone in non-obese polycystic ovary syndrome women with insulin resistance].
Tan J, Zhou GJ, Wang QY, Liu TT, Cao Q, Huang W. Tan J, et al. Zhonghua Fu Chan Ke Za Zhi. 2021 Jul 25;56(7):467-473. doi: 10.3760/cma.j.cn112141-20210424-00224. Zhonghua Fu Chan Ke Za Zhi. 2021. PMID: 34304438 Clinical Trial. Chinese.
After treatment for 6 months, body mass index [metformin group (21.61.6) kg/m(2), rosiglitazone group (21.71.7) kg/m(2)] decreased in both groups (both P<0.01); decreased LH/FSH ratio (metformin group 1.670.80, rosiglitazone group 1.700.83) was also …
After treatment for 6 months, body mass index [metformin group (21.61.6) kg/m(2), rosiglitazone group (21.71.7) kg/m(2)] decre …
224 results